⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
WHWK News
Whitehawk Therapeutics, Inc. Common Stock
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
prnewswire.com
WHWK
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
prnewswire.com
WHWK
Form 8-K
sec.gov
WHWK
INCY
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
prnewswire.com
WHWK
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
prnewswire.com
WHWK
Form 8-K
sec.gov
WHWK
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
prnewswire.com
WHWK
百奧賽圖與Whitehawk Therapeutics達成全球合作，共同開發創新雙特異性抗體ADC
businesswire.com
WHWK
バイオサイトジェンとホワイトホーク・セラピューティクス、二重特異性抗体ADC開発のためのグローバル提携に合意
businesswire.com
WHWK
Biocytogen e Whitehawk Therapeutics sottoscrivono una collaborazione globale orientata allo sviluppo di ADC basati su anticorpi bispecifici
businesswire.com
WHWK